Drugs / PF-07976016
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07015918 | Jun → Jul 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06910839 | Mar → May 2025 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT06670170 | Nov → Dec 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06106009 | Oct 2023 → Aug 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06717425 | Dec 2024 → Oct 2025 | obesity disorder | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07976016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06910839 ↗ |
| Route | Oral | “ADMINISTERED ORALLY” NCT06670170 ↗ |